IngentaConnect Rabeprazole containing triple therapy to eradicate Helicobacter p...

Authors: CARDENAS, V. M.¹; GRAHAM, D. Y.; EL-ZIMAITY, H. M. T.; OPEKUN, A. R.²; CAMPOS, A.³; CHAVEZ, A.⁴; GUERRERO, L.³

Source: Alimentary Pharmacology & Therapeutics, Volume 23, Number 2, January 2006 , pp. 295-301(7)

Publisher: Blackwell Publishing

Abstract:

Summary Background

Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. Aim

To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study population. Methods

Adults from Ciudad Juarez with H. pylori infections identified by culture or histology received rabeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1 g, each b.d. for 7 days. Outcome was assessed by ¹³C-urea breath test carried out 4+ weeks after treatment. Results

A total of 111 patients were enrolled and evaluated by urea breath test; 102 completed the full 7 days therapy. Two deviated from protocol, and five stopped because of adverse events. The cure rate (intention-to-treat) was 85% (95% CI: 78–91%); the per-protocol cure rate was 85% (95% CI: 78–91%). Side-effects were not serious and only 6.6% of those with adverse events stopped medication. Only three isolates were clarithromycin-resistant and none was cured. Compliance explained most of the successes. Conclusions

In the study population a 7-day rabeprazole triple eradication therapy was both effective and well-tolerated. Clarithromycin resistance was uncommon. We observed a slightly better outcome but consistent with results from recent large studies in US populations.

Document Type: Research article

DOI: 10.1111/j.1365-2036.2006.02755.x

Affiliations: 1: El Paso Regional Campus, University of Texas School of Public Health, El Paso, TX, USA 2: Department of Pathology, Veterans Affairs Medical Center, Houston, TX, USA 3: Mexican Institute for Social Security, General Hospital for Region 6, Ciudad Juarez, Chihuahua, Mexico 4: Gastroenterology Specialists of El Paso, El Paso, TX, USA

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border